- Datum18.09.2025
- Uhrzeit17:00 - 18:00 Uhr
- Veranstalter
stock3
Merus N.V. Aktie
Verkaufen
Kaufen
Merus N.V. Chart
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Merus N.V. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-0,40 %
Intraday
-1,07 %
1 Woche
0,84 %
1 Monat
61,27 %
Seit Jahresbeginn
35,09 %
1 Jahr
203,02 %
3 Jahre
470,35 %
5 Jahre
Passender Service zu Merus N.V.
Webinar zu Merus N.V.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)33,190-70,647
- Jahrestief / Hoch ($)33,190-70,647
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Merus N.V.
Keine Dividenden verfügbar
Termine von Merus N.V.
- Okt30Merus N.V.Q3 2025 Earnings Release
- Mär4Merus N.V.Q4 2025 Earnings Release
- Mai13Merus N.V.Q1 2026 Earnings Release
Beschreibung
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
